IN8bio Announces Oral Presentation at the Upcoming American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting

Rhea-AI Summary

IN8bio, Inc. (Nasdaq: INAB) will present on Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product at the ASGCT 2024 Annual Meeting. The presentation focuses on novel production platforms and will take place on May 10th, 2024, in Baltimore, MD. The data will be available online post-presentation.

NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced an oral presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and virtually.

Details of the oral presentation are as follows:

Title: Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product; Immunophenotyping Gene Expression

Session Type: In-Person Oral Presentation

Session Title: Novel Production Platforms

Abstract Number: 282

Location: Ballroom 2

Presentation Date/Time: Friday, May 10th at 3:45 pm – 4:00 pm ET

Abstracts are available at https://annualmeeting.asgct.org/. The data are embargoed until 6:00 a.m. ET on the presentation day, Wednesday May 10, 2024. A copy of the presentation will be available at https://in8bio.com once the presentation concludes.

About IN8bio

IN8bio is a clinical-stage biopharmaceutical company developing gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess unique properties, including the ability to differentiate between healthy and diseased tissue. The company’s lead program, INB-400, is in a Phase 2 trial in glioblastoma multiforme (GBM). Additional programs include Phase 1 trials in solid and hematologic tumors, including INB-200 for GBM and INB-100 for patients with hematologic malignancies undergoing transplantation. For more information about IN8bio, visit www.IN8bio.com. 

Corporate Contact:
IN8bio, Inc.
Glenn Schulman, PharmD, MPH
203.494.7411
gdschulman@IN8bio.com

Investors
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com

Media Contact
Kimberly Ha
KKH Advisors
917.291.5744
kimberly.ha@kkhadvisors.com

FAQ

What is the title of the presentation by IN8bio at the ASGCT 2024 Annual Meeting?

The title of the presentation is 'Healthy Donor vs Patient Manufactured Autologous Deltex DRI Product.'

When will the presentation by IN8bio take place at the ASGCT 2024 Annual Meeting?

The presentation by IN8bio is scheduled for Friday, May 10th, 2024, at 3:45 pm – 4:00 pm ET.

Where will the ASGCT 2024 Annual Meeting be held?

The ASGCT 2024 Annual Meeting will take place in Baltimore, MD, and virtually.

Where can I find more information about the presentation and abstracts?

More information about the presentation and abstracts can be found at https://annualmeeting.asgct.org/.

When will the data from the presentation be available online?

The data from the presentation will be available online at 6:00 a.m. ET on Wednesday, May 10, 2024.